/
Castle Biosciences is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett s esophagus ( BE ), atopic dermatitis ( AD ), uveal melanoma ( UM ). Since our inception in 2008, it has been our vision to transform disease management by keeping people first: patients, clinicians, employees and investors.
The business is unprofitable at the operating level (-12.44% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 3.7%, steady but not accelerating. Margins contracted 15.0pp, which offsets some of the top-line progress.
Free cash flow declined 22% versus the prior year, cash generation momentum has weakened. ROIC dropped from 1.20% to -6.83%, capital efficiency is deteriorating.
Profitability & Returns
Revenue (TTM)
$340M
▲ +3.7% YoY
Net Income (TTM)
-$13M
▼ -232.4% YoY
Op. Margin
-9.79%
▼ -15.0pp YoY
ROIC
-5.25%
▼ -8.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$5M
▼ -22.5% YoY
Op. Cash Flow (TTM)
$48M
▼ -0.8% YoY
Net Debt
-$225M
Net Cash Position
Cash & Equiv.
$262M
5Y CAGR: +40.6%
5Y CAGR: +40.8%
Continue Research